(BLTE) Belite Bio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.715m USD | Total Return: 112.4% in 12m
Avg Turnover: 16.2M
Warnings
High Debt/EBITDA (5.9) with thin interest coverage (-42104.0)
High Debt while negative Cash Flow
Interest Coverage Ratio -42104.0 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Belite Bio, Inc. (BLTE) is a clinical-stage biotechnology firm focused on developing oral therapeutics for retinal degenerative diseases and metabolic disorders. The company’s primary candidate, Tinlarebant, is currently in Phase 3 clinical trials targeting Stargardt Disease and Geographic Atrophy, conditions for which there are limited existing treatment options. The biotechnology sector often requires significant capital for long-term research and development before reaching commercialization stages.
The company is also advancing its preclinical pipeline with LBS-009, an oral therapy designed to treat liver diseases such as non-alcoholic fatty liver disease and type 2 diabetes. As a subsidiary of Lin Bioscience International Ltd., Belite Bio operates within the high-risk, high-reward biopharmaceutical industry where success is heavily dependent on regulatory approval cycles. Investors may find additional insights on these clinical milestones by exploring the data available on ValueRay.
Based in San Diego, California, the firm utilizes a business model centered on targeting unmet medical needs through specialized protein-binding therapies. This approach aims to preserve retinal tissue integrity in patients suffering from progressive vision loss.
- Tinlarebant Phase 3 clinical trial results determine primary valuation and market viability
- FDA approval timeline for Stargardt disease treatment impacts long-term revenue projections
- Geographic Atrophy market penetration faces competition from established injectable therapies
- Clinical trial funding requirements necessitate potential dilutive secondary equity offerings
- Expansion of LBS-009 pipeline into metabolic diseases drives future growth optionality
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 14.55 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.05 > 3% & CFO -37.0m > Net Income -77.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 50.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.5m) vs 12m ago 6.63% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -42.1k > 6 (EBITDA TTM -83.7m / Interest Expense TTM 2.00k) |
| A: 0.62 (Total Current Assets 494.3m - Total Current Liabilities 9.88m) / Total Assets 780.6m |
| B: -0.24 (Retained Earnings -185.3m / Total Assets 780.6m) |
| C: -0.18 (EBIT TTM -84.2m / Avg Total Assets 466.3m) |
| D: -18.45 (Book Value of Equity -185.8m / Total Liabilities 10.1m) |
| Altman-Z'' = -17.29 = D |
As of May 24, 2026, the stock is trading at USD 137.30 with a total of 107,128 shares traded.
Over the past week, the price has changed by -3.99%,
over one month by -17.99%,
over three months by -27.45% and
over the past year by +112.44%.
Belite Bio has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy BLTE.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 211.5 | 54% |
P/B = 8.058
Revenue TTM = 0.0 USD
EBIT TTM = -84.2m USD
EBITDA TTM = -83.7m USD
Long Term Debt = 188k USD (estimated: total debt 429k - short term 241k)
Short Term Debt = 241k USD (from shortTermDebt, last quarter)
Debt = 429k USD (from shortLongTermDebtTotal, last quarter) (leases 429k already included)
Net Debt = -492.0m USD (calculated: Debt 429k - CCE 492.4m)
Enterprise Value = 5.22b USD (5.72b + Debt 429k - CCE 492.4m)
Interest Coverage Ratio = -42.1k (Ebit TTM -84.2m / Interest Expense TTM 2.00k)
EV/FCF = -140.5x (Enterprise Value 5.22b / FCF TTM -37.2m)
FCF Yield = -0.71% (FCF TTM -37.2m / Enterprise Value 5.22b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 6.69 (Enterprise Value 5.22b / Total Assets 780.6m)
Interest Expense / Debt = 0.47% (Interest Expense 2.00k / Debt 429k)
Taxrate = 21.0% (US default 21%)
NOPAT = -66.5m (EBIT -84.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 50.02 (Total Current Assets 494.3m / Total Current Liabilities 9.88m)
Debt / Equity = 0.00 (Debt 429k / totalStockholderEquity, last quarter 770.5m)
Debt / EBITDA = 5.87 (negative EBITDA) (Net Debt -492.0m / EBITDA -83.7m)
Debt / FCF = 13.24 (negative FCF - burning cash) (Net Debt -492.0m / FCF TTM -37.2m)
Total Stockholder Equity = 338.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.64% (Net Income -77.6m / Total Assets 780.6m)
RoE = -14.83% (Net Income TTM -77.6m / Total Stockholder Equity 523.4m)
RoCE = -16.08% (EBIT -84.2m / Capital Employed (Equity 523.4m + L.T.Debt 188k))
RoIC = -23.89% (negative operating profit) (NOPAT -66.5m / Invested Capital 278.5m)
WACC = 7.06% (E(5.72b)/V(5.72b) * Re(7.06%) + D(429k)/V(5.72b) * Rd(0.47%) * (1-Tc(0.21)))
Discount Rate = 7.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 9.55%
[DCF] Fair Price = unknown (Cash Flow -37.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.73 | # QB: -2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.67 | Chg30d=+0.00% | Revisions=-43% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.13 | Chg30d=-1.85% | Revisions=N/A | GrowthEPS=+7.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.79 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+136.8% | GrowthRev=+611.6%
[Analyst] Revisions Ratio: -43%